1. Background
2. Objectives
3. Methods
4. Results
| Biological Process | Number of Proteins (Among 358) | Proteins in % | P Value |
|---|---|---|---|
| Adhesion | |||
| Cell-cell adhesion | 35 | 9.8 | 1.9 E-15 |
| Actin cytoskeleton organization | 16 | 4.5 | 4.7 E-07 |
| Wnt signaling pathway, planar cell polarity pathway | 10 | 2.8 | 3.4 E-04 |
| Cell-matrix adhesion | 8 | 2.2 | 5.6 E-03 |
| Protein synthesis | |||
| Translational initiation | 28 | 7.8 | 1.4 E-17 |
| Translation | 28 | 7.8 | 7.2 E-11 |
| rRNA processing | 23 | 6.4 | 8.6 E-09 |
| Protein folding | 14 | 3.9 | 3.8 E-04 |
| Extracellular matrix disassembly | 9 | 2.5 | 4.4 E-04 |
| tRNA aminoacylation for protein translation | 6 | 1.7 | 2.5 E-03 |
| ECM organization | |||
| Proteolysis | 22 | 6.1 | 8.7 E-03 |
| Extracellular matrix organization | 17 | 4.7 | 1.9 E-05 |
| Collagen catabolic process | 7 | 2.0 | 4.1 E-03 |
| Fibrinolysis | 5 | 1.4 | 1.4 E-03 |
| Collagen fibril organization | 5 | 1.4 | 1.3 E-02 |
| Inflammation | |||
| Innate immune response | 21 | 5.9 | 3.4 E-03 |
| Leukocyte migration | 11 | 3.1 | 6.6 E-04 |
| T cell receptor signaling pathway | 11 | 3.1 | 2.9 E-03 |
| Stimulatory C-type lectin receptor signaling pathway | 9 | 2.5 | 3.6 E-03 |
| Fc-gamma receptor signaling pathway involved in phagocytosis | 9 | 2.5 | 1.1 E-02 |
| Antigen processing and presentation of exogenous peptide antigen via MHC | 8 | 2.2 | 7.1 E-04 |
| Defense response to Gram-negative bacterium | 7 | 2.0 | 1.9 E-03 |
| Defense response to Gram-positive bacterium | 6 | 1.7 | 5.2 E-02 |
| Phagocytosis | 5 | 1.4 | 2.7 E-02 |
| Metabolism | |||
| Metabolic process | 13 | 3.6 | 6.9 E-04 |
| Lipid metabolic process | 9 | 2.5 | 3.4 E-02 |
| Fatty acid beta-oxidation | 7 | 2.0 | 5.7 E-04 |
| Gluconeogenesis | 6 | 1.7 | 3.7 E-03 |
| Cholesterol biosynthetic process | 5 | 1.4 | 1.2 E-02 |
| Cellular aldehyde metabolic process | 4 | 1.1 | 1.9 E-03 |
| Very long-chain fatty acid metabolic process | 3 | 0.8 | 4.2 E-02 |
| Glycogen catabolic process | 4 | 1.1 | 1.3 E-02 |
| Krebs cycle/energy | |||
| Tricarboxylic acid cycle | 7 | 2.0 | 5.2 E-05 |
| Mitochondrial ATP synthesis coupled proton transport | 5 | 1.4 | 1.4 E-03 |
| ATP biosynthetic process | 5 | 1.4 | 4.7 E-03 |
| Miscellaneous | |||
| Oxidation-reduction process | 36 | 10.1 | 7.2 E-07 |
| Morphogenesis of an epithelium | 3 | 0.8 | 4.2 E-02 |
| Epidermis development | 6 | 1.7 | 5.2 E-02 |
aP value was calculated automatically using Gene Ontology software.
bProteins showing a fold modulation in Nodules superior to 1.2 and a significant Q-value were analyzed for enriched biological processes based on gene ontology in Gene Ontology (GO) software. As expected, inflammation was highlighted as a relevant event in nodules. However, less expected biological processes like extracellular matrix organization, adhesion, synthesis, and metabolism of proteins were identified and are summarized in Table 1. Table 2 summarizes significantly modulated proteins in the MS analysis.
| ID Uniprot | Biological Pathway | Protein Name UniProt | Gene Symbol | Fold Change [NO vs. NLS] Paired Effect | BH Q-Value |
|---|---|---|---|---|---|
| P17213 | Antimicrobial activity | Bactericidal permeability-increasing protein | BPI | 10.17 | ** |
| P59665 | Neutrophil defensin 1 | DEFA1B; DEFA1 | 11.34 | *** | |
| P59666 | Neutrophil defensin 3 | DEFA3 | 11.34 | *** | |
| P24158 | Neutrophil activation | Myeloblastin | PRTN3 | 41.68 | ** |
| P20160 | Azurocidin | AZU1 | 5.61 | ** | |
| P08311 | Cathepsin G | CTSG | 7.07 | *** | |
| P05107 | Cell-ECM interaction | Integrin beta-2 | ITGB2 | 21.06 | *** |
| P51659 | Lipid metabolism | Peroxisomal multifunctional enzyme type 2 | HSD17B4 | 2.48 | * |
| P61916 | Epididymal secretory protein E1 | NPC2 | 2.34 | * | |
| P02649 | Apolipoprotein E | APOE | 1.66 | * | |
| P43034 | Platelet-activating factor acetylhydrolase IB subunit alpha | PAFAH1B1 | -1.36 | * | |
| P49327 | Fatty acid synthase | FASN | -1.37 | * | |
| P00387 | NADH-cytochrome b5 reductase 3 | CYB5R3 | -1.81 | ** | |
| Q13011 | Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial | ECH1 | -1.82 | ** | |
| Q96K12 | Fatty acyl-CoA reductase 2 | FAR2 | -2.18 | *** | |
| Q6E213 | Acyl-CoA wax alcohol acyltransferase 2 | AWAT2 | -2.46 | *** | |
| P14324 | Farnesyl pyrophosphate synthase | FDPS | -2.53 | * | |
| P33121 | Long-chain-fatty-acid--CoA ligase 1 | ACSL1 | -3.27 | ** | |
| Q15392 | Delta(24)-sterol reductase | DHCR24 | -4.16 | * | |
| P11310 | Medium-chain specific acyl-CoA dehydrogenase, mitochondrial | ACADM | -4.20 | ** | |
| O95864 | Fatty acid desaturase 2 | FADS2 | -11.85 | *** |
Abbreviations: NO, nodule; NLS, non-lesional skin
a*0.01 < P value < 0.05; **0.005 < P value < 0.01; ***P value < 0.005
bID Uniprot: identification number: Uniprot Data base. Fold change was calculated using Genedata software as described in Materials and Methods.
| Protein ID | Nodule vs. NLS | Papule vs. NLS | Function | ||
|---|---|---|---|---|---|
| Fold Change | P Value | Fold Change | P Value | ||
| CXCL8 (IL8) | 560 | *** | 10 | 0.08 | Chemotactic factor (neutrophils. basophils and T-cells) |
| IL6 | 381 | *** | 8.4 | * | Th17 activation |
| TNF | 21 | *** | 3.8 | 0.08 | Th17/Th1 activation cytokine released |
| CXCL11 (I-TAC) | 4.6 | ** | 2.7 | 0.08 | Chemotactic for interleukin-activated T-cells |
| IL17A | 51 | *** | 2.1 | 0.37 | Th17 activation cytokine released |
| CCL4 (MIP1-Beta) | 40 | *** | 3.0 | 0.25 | Chemotactic for B and T lymphocytes, dendritic cells, phagocytes |
| CCL20 (MIP-3alpha) | 8.8 | *** | 1.8 | 0.40 | Th17 activation cytokine released |
| IL1B (IL1Beta) | 8.6 | *** | 2.4 | 0.19 | Potent proinflammatory cytokine, Th17 activation |
| CCL3 (MIP-1 alpha) | 5.0 | ** | 1.7 | 0.50 | Recruitment and activation of polymorphonuclear leukocytes |
| IL17F (ML1) | 3.7 | *** | 1.4 | 0.58 | Th17 activation cytokine released |
| IL27 | 3.1 | ** | 1.4 | 0.58 | T cell proliferation |
| IL33 | 1.8 | * | 1.3 | 0.58 | Maturation of Th2 cells and the activation of mast cells, basophils, eosinophils and natural killer cells. |
| IL15 | 1.4 | 0.14 | 1.1 | 0.79 | Th2 activation |
| CSF2 (GM-CSF) | 1.2 | 0.83 | -1.2 | 0.72 | Th17 activation cytokine released |
| CX3CL1 (Fractalkine) | 1.1 | 0.84 | 1.2 | 0.72 | Chemotactic factor (neutrophils, basophils, and T-cells) |
| IL13 | 1.1 | 0.87 | 1.2 | 0.55 | Th2 activation/cytokine release |
| IL9 | -1.1 | 0.67 | 1.1 | 0.90 | Th2 activation/cytokine release |
| IL5 | -1.2 | 0.77 | -1.3 | 0.55 | Th2 activation/cytokine release |
| IL21 | -1.5 | 0.29 | 1.1 | 0.79 | Th17 activation cytokine released |
| IL10 | -2.4 | 0.29 | -2.4 | 0.40 | Th2 activation/cytokine release |
| IL7 | -5.1 | ** | -1.5 | 0.55 | B and T cell development, lymphoid development, B cell maturation |
Abbreviations: ND, not detected; NS, P > 0.05; NLS, Non-lesional Skin; NT, not tested
a*P < 0.05; **P <0.01; ***P < 0.001
